REYKJAVIK, Iceland, June 30 /PRNewswire-FirstCall/ -. deCODE genetics
(Nasdaq: DCGN) today announced that it will webcast live the presentations
at the company's annual R&D event to be held in New York.
The presentations will be delivered on Monday, June 30, beginning at
1pm Eastern Time/5pm GMT/6pm British Summer time, at the Gansevoort hotel
in New York. The webcast is expected to last approximately three and a half
hours. The webcast can be accessed through the Investors page on deCODE's
website, http://www.decode.com, and those interested in listening should log on a
few minutes in advance in order to download any software or complete any
sign-in that may be required. The webcast will be archived for at least one
week.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human
genetics to the development of diagnostics and drugs for common diseases.
deCODE is a global leader in gene discovery -- our population approach and
resources have enabled us to isolate key genes contributing to major public
health challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease.
Through its CLIA-registered laboratory, deCODE is offering a growing range
of DNA-based tests for gauging risk and empowering prevention of common
diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for
atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE
ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of
glaucoma. deCODE is delivering on the promise of the new genetics.(SM)
Visit us on the web at http://www.decode.com; on our diagnostics website at
http://www.decodediagnostics.com; and, for our pioneering personal genome analysis
service, at http://www.decodeme.com.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of events, to
differ materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating to our
ability to obtain financing and to form collaborative relationships,
uncertainty regarding potential future deterioration in the market for
auction rate securities which could result in additional permanent
impairment charges, our ability to develop and market diagnostic products,
the level of third party reimbursement for our products, risks related to
preclinical and clinical development of pharmaceutical products, including
the identification of compounds and the completion of clinical trials, the
effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships, the
effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, including,
without limitation, the risk factors identified in our most recent Annual
Report on Form 10-K and any updates to those risk factors filed from time
to time in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future events or
otherwise.
Contacts:
Gisli Arnason Joy Bessenger
+354 570 1825 +1 212 481 3891
gisli.arnason@decode.is joy.bessenger@decode.is
See Also:
- New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
- Common causes and symptoms of Hypertension
- Grandmother is Inspiration for Winner of Tobacco Free Florida YouCare Contest
- Cardiac Science Announces Inclusion in Russell 3000 Index
- Arthritis Treatment - Diets As a Remedy of Arthritis Pain
[Via Healthcare]
0 коментарі:
Post a Comment